We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis’ Gleevec Gets Further Indication for Children With ALL
Novartis’ Gleevec Gets Further Indication for Children With ALL
January 25, 2013
The FDA is expanding the indication for Novartis’ cancer drug Gleevec to treat children with acute lymphoblastic leukemia (ALL) in combination with chemotherapy.